FR2898497B1 - Utilisation de l'apratastat ou du (s)-n-hydroxy-4-(4-but-2- ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carbo xamide dans le traitement de pathologies inflammatoires cutanees - Google Patents

Utilisation de l'apratastat ou du (s)-n-hydroxy-4-(4-but-2- ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carbo xamide dans le traitement de pathologies inflammatoires cutanees

Info

Publication number
FR2898497B1
FR2898497B1 FR0602429A FR0602429A FR2898497B1 FR 2898497 B1 FR2898497 B1 FR 2898497B1 FR 0602429 A FR0602429 A FR 0602429A FR 0602429 A FR0602429 A FR 0602429A FR 2898497 B1 FR2898497 B1 FR 2898497B1
Authority
FR
France
Prior art keywords
apratastat
ynyloxy
thiomorpholin
benzenesulfonyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0602429A
Other languages
English (en)
Other versions
FR2898497A1 (fr
Inventor
Thibaud Biadatti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR0602429A priority Critical patent/FR2898497B1/fr
Priority to CA002645327A priority patent/CA2645327A1/fr
Priority to PCT/FR2007/050939 priority patent/WO2007107663A2/fr
Priority to EP07731755A priority patent/EP1998779A2/fr
Publication of FR2898497A1 publication Critical patent/FR2898497A1/fr
Application granted granted Critical
Publication of FR2898497B1 publication Critical patent/FR2898497B1/fr
Priority to US12/232,456 priority patent/US20090137569A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
FR0602429A 2006-03-20 2006-03-20 Utilisation de l'apratastat ou du (s)-n-hydroxy-4-(4-but-2- ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carbo xamide dans le traitement de pathologies inflammatoires cutanees Expired - Fee Related FR2898497B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0602429A FR2898497B1 (fr) 2006-03-20 2006-03-20 Utilisation de l'apratastat ou du (s)-n-hydroxy-4-(4-but-2- ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carbo xamide dans le traitement de pathologies inflammatoires cutanees
CA002645327A CA2645327A1 (fr) 2006-03-20 2007-03-16 Utilisation du (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide ou du (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxamide dans le traitement de pathologies inflammatoires cutanees
PCT/FR2007/050939 WO2007107663A2 (fr) 2006-03-20 2007-03-16 Utilisation du (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phényl}sulfonyl)-2,2-diméthyl-3-thiomorpholine carboxamide ou du (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide dans le traitement de pathologies inflammatoires cutanées
EP07731755A EP1998779A2 (fr) 2006-03-20 2007-03-16 Utilisation du (3s)-n-hydroxy-4-({4-ý(4-hydroxy-2-butynyl)oxy]phényl}sulfonyl)-2,2-diméthyl-3-thiomorpholine carboxamide ou du (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide dans le traitement de pathologies inflammatoires cutanées
US12/232,456 US20090137569A1 (en) 2006-03-20 2008-09-17 Administration of (3S)-N-hydroxy-4-(sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (S)-N_hydroxy-4-[4_(but-2-ynyloxy)phenylsulfonyl]-2,2-dimethyl thimomorpholine-3-carboxamide for preventing and/or treating inflammatory skin pathologies/afflictions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0602429A FR2898497B1 (fr) 2006-03-20 2006-03-20 Utilisation de l'apratastat ou du (s)-n-hydroxy-4-(4-but-2- ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carbo xamide dans le traitement de pathologies inflammatoires cutanees

Publications (2)

Publication Number Publication Date
FR2898497A1 FR2898497A1 (fr) 2007-09-21
FR2898497B1 true FR2898497B1 (fr) 2008-05-16

Family

ID=37057052

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0602429A Expired - Fee Related FR2898497B1 (fr) 2006-03-20 2006-03-20 Utilisation de l'apratastat ou du (s)-n-hydroxy-4-(4-but-2- ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carbo xamide dans le traitement de pathologies inflammatoires cutanees

Country Status (5)

Country Link
US (1) US20090137569A1 (fr)
EP (1) EP1998779A2 (fr)
CA (1) CA2645327A1 (fr)
FR (1) FR2898497B1 (fr)
WO (1) WO2007107663A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2597084T3 (en) 2010-07-08 2016-08-15 Kaken Pharma Co Ltd N-HYDROXYFORMAMIDE DERIVATIVE AND MEDICINAL CONTAINING SAME
GB2483499A (en) 2010-09-10 2012-03-14 S3 Res & Dev Ltd Diagnostics and Analysis of a Set Top Box
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
AR035313A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
AU2003284001A1 (en) * 2002-10-07 2004-05-04 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives
GT200500139A (es) * 2004-06-08 2005-07-25 Metodo para la preparacion de acidos hidroxamicos

Also Published As

Publication number Publication date
CA2645327A1 (fr) 2007-09-27
EP1998779A2 (fr) 2008-12-10
WO2007107663A3 (fr) 2007-11-22
FR2898497A1 (fr) 2007-09-21
US20090137569A1 (en) 2009-05-28
WO2007107663A2 (fr) 2007-09-27

Similar Documents

Publication Publication Date Title
FR2882654B1 (fr) Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
CY2016040I1 (el) Επιλογες θεραπειας για τη νοσο του fabry
DK2276485T3 (da) Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom
BRPI0811411A2 (pt) "kit de tratamento de um conduto de circulação do sangue"
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
DK2609855T3 (da) Balanceret fysiologisk overvågnings- og behandlingssystem
BRPI0913915A2 (pt) benzoxazinas, benzotiazinas, e compostos relacionados tendo atividade inibitória de nos
BRPI0811473A2 (pt) Compostos hidrossolúveis de magnésio como agentes de limpeza e métodos de utilização dos mesmos.
DK1720554T3 (da) Anvendelse af meloxicam til behandling af luftvejssygdomme hos svin
DE602005015418D1 (de) Überwachungssystem für den menschlichen körper
FR2902324B1 (fr) Utilisation d'acide ellagique pour le traitement de la canitie
DK3279663T3 (da) Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme
DK1778239T3 (da) Adenosin-a3-receptor-agonister til behandling af sygdomme forbundet medtørre øjne, herunder sjögrens syndrom
FR2928832B1 (fr) Orthese de poignet, destinee au traitement du syndrome du canal carpien
NO20081539L (no) Middel for behandling av betennelsestarmsykdom
BRPI0808246A2 (pt) "fralda descartável".
DK1959828T3 (da) Diagnosticering af en sygdomstilstand i huden ved brug af impedans
SI2148667T1 (sl) Uporaba derivatov cikloheksanheksola pri zdravljenju okularnih bolezni
FR2899476B1 (fr) Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
FR2883182B1 (fr) Composition de vitamines utiles dans le traitement des maladies oculaires
FR2913886B1 (fr) Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
FR2934052B1 (fr) Dosage de l'activite du facteur tissulaire circulant
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson
DE602005005145D1 (de) Medizinische Elektrodenanordnung mit Möglichkeit zur Überwachung der Behandlung

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

ST Notification of lapse

Effective date: 20161130